References

Althanoon Z, Faisal I M Ahmad, Ahmad A, Merkhan M M. Pharmacological Aspects of Statins Are Relevant to Their Structural and Physicochemical Properties. Systematic Reviews in Pharmacy. 2020; 11:(7)167-171 https://doi.org/10.31838/srp.2020.7.27

Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 2021; 35:(4)853-864 https://doi.org/10.1007/s10557-021-07147-5

Cannon CP, Blazing MA, Giugliano RP Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372:(25)2387-2397 https://doi.org/10.1056/NEJMoa1410489

Chisnell J, Marshall T, Hyde C, Zhelev Z, Fleming LE. A content analysis of the representation of statins in the British newsprint media. BMJ Open. 2017; 7:(8) https://doi.org/10.1136/bmjopen-2016-012613

Cybulska B, Kłosiewicz-Latoszek L. Landmark studies in coronary heart disease epidemiology. The Framingham Heart Study after 70 years and the Seven Countries Study after 60 years. Kardiol Pol. 2019; 77:(2)173-180 https://doi.org/10.5603/KP.a2019.0017

DuBroff R. A Reappraisal of the Lipid Hypothesis. The American Journal of Medicine. 2018; 131:(9)993-997 https://doi.org/10.1016/j.amjmed.2018.04.027

Electronic Medicines Compendium. Nilemdo 180mg film-coated tablets SmPC. 2020a. https://www.medicines.org.uk/emc/product/11743/smpc#gref (accessed 23 November 2021)

Electronic Medicines Compendium. Nustendi 180mg/10mg SmPC. 2020b. https://www.medicines.org.uk/emc/product/11744/smpc (accessed 23 November 2021)

Mach F, Baigent C, Catapano AL 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41:(1)111-188 https://doi.org/10.1093/eurheartj/ehz455

Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015; 161:(1)161-172 https://doi.org/10.1016/j.cell.2015.01.036

Jia X, Virani SS. CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins?. J Am Heart Assoc. 2019; 8:(7) https://doi.org/10.1161/JAHA.119.012352

National Institute for Health and Care Excellence (NICE). Resource impact report: Alirocumab (TA393) and evolocumab (TA394) for treating primary hypercholesterolaemia and mixed dyslipidaemia. 2016. https://www.nice.org.uk/guidance/ta393/resources/resource-impact-report-pdf-2543362381 (accessed 23 November 2021)

National Institute for Health and Care Excellence (NICE). Lipid modification therapy for preventing cardiovascular disease. 2021a. https://pathways.nice.org.uk/pathways/cardiovascular-disease-prevention/lipid-modification-therapy-for-preventing-cardiovascular-disease (accessed 23 November 2021)

National Institute for Health and Care Excellence (NICE). Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia. 2021b. https://www.nice.org.uk/guidance/ta694 (accessed 23 November 2021)

NHS England. Lipid management pathway. 2020. https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/Lipid-Management-Pathway-NEW.pdf (accessed 23 November 2021)

NHS England. NHS cholesterol-busting jab to save thousands of lives. 2021a. https://www.england.nhs.uk/2021/09/nhs-cholesterol-busting-jab-to-save-thousands-of-lives/ (accessed 23 November 2021)

NHS England. Statin intolerance pathway. 2021b. https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/08/Statin-Intolerance-Pathway-NEW.pdf (accessed 23 November 2021)

NHS England and NHS Improvement. Primary Care Networks – plans for 2021/22 and 2022/23. 2021. https://www.england.nhs.uk/wp-content/uploads/2021/08/B0828-i-gp-contract-letter-pvns-21-22-and-22-23.pdf (accessed 23 November 2021)

NHS Health Check. CVDPREVENT: A National Audit for Primary Care. 2021. https://www.healthcheck.nhs.uk/commissioners-and-providers/data/cvdprevent/ (accessed 23 November 2021)

Oh M, Kim H, Shin EW Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation. BMC Cardiovascular Disorders. 2019; 19:(1) https://doi.org/10.1186/s12872-019-1184-2

Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019; 4:(3)206-213 https://doi.org/10.1001/jamacardio.2018.4936

Shih CW, Hauser ME, Aronica L, Rigdon J, Gardner CD. Changes in blood lipid concentrations associated with changes in intake of dietary saturated fat in the context of a healthy low-carbohydrate weight-loss diet: a secondary analysis of the Diet Intervention Examining The Factors Interacting with Treatment Success (DIETFITS) trial. Am J Clin Nutr. 2019; 109:(2)433-441 https://doi.org/10.1093/ajcn/nqy305

Trapani L, Segatto M, Pallottini V. Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic “power station”. World J Hepatol. 2012; 4:(6)184-190 https://doi.org/10.4254/wjh.v4.i6.184

Visseren FLJ, Mach F, Smulders YM 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021; 42:(34) https://doi.org/10.1093/eurheartj/ehab484

The 10-year CVD ambitions for England – one year on. 2020. https://publichealthmatters.blog.gov.uk/2020/02/06/the-10-year-cvd-ambitions-for-england-one-year-on/ (accessed 23 November 2021)

Cardiology
Medicines Management

The role of bempedoic acid in the management of dyslipidaemia

02 December 2021
Clinical Focus
02 December 2021
Volume 3 · Issue 12

Abstract

Bempedoic acid is a new oral lipid-lowering therapy which has been licenced for use in the United Kingdom. It can be used alone, with a statin, or with other lipid-lowering therapies where the target level for low density lipoprotein has not been achieved with these therapies alone. Bempedoic acid with ezetimibe can be prescribed for people who are unable to tolerate statins. This combination has received NICE approval following a technology appraisal. This paper discusses the place for of bempedoic acid as a lipid lowering drug and consider the mode of action, licensed indications, adverse drug reactions and the NICE technology appraisal recommendations.

Cardiovascular disease is back at the front and centre of the healthcare agenda following the publication of Public Health England’s 10-year ambition for reducing the burden of cardiovascular disease (CVD) (Waterall, 2020), the CVD-Prevent programme (NHS Health Check, 2021) and the recent announcement of the priorities for primary care for 2021/2 and 2022/3 (NHS England and NHS Improvement, 2021).

This refreshed focus on CVD prevention aims to improve the identification and management of three key risk factors: atrial fibrillation, blood pressure and cholesterol (the ABC of CVD) with the addition of heart failure, which is also seen as a priority for intervention (NHS, 2018). With respect to dyslipidaemia, the aim is to identify and manage dyslipidaemia more effectively and to increase awareness and detection of familial hypercholesterolaemia (FH) (Waterall, 2020). The 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice also highlight the importance of effective lipid management (Visseren et al, 2021).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month

Register
Or continue by

Signing in with your registered email address

Bempedoic acid
lipid-lowering
LDL-cholesterol
statin intolerance